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Rheumatoid arthritis (RA) and osteoarthritis (OA) are inflamma-
tory joint diseases, characterized by pain and structural damage.
Besides prostaglandins, usually targeted by non-steroidal anti-in-
flammatory drugs, other lipids, including fatty acids, phospholipids
and other bioactive lipid mediators derived from fatty acids could
also contribute to RA and OA.
In this review, we present evidence for the role of fatty acids and
derivatives in RA and OA by summarizing findings related to their
presence in serum and synovial fluid, as well as their association
with clinical characteristics and effects on RA and OA tissues
in vitro. Finally, a more direct evidence for their role in RA and OA
derived from intervention studies in humans or mouse models of
disease is summarized. Based on the presented data, we present a
research agenda, in which some key unresolved questions
regarding the role of lipids in RA and OA are formulated.
© 2016 Elsevier Ltd. All rights reserved.Introduction
Rheumatoid arthritis (RA) and osteoarthritis (OA) are joint diseases characterized by different
pathophysiological mechanisms, but displaying common clinical characteristics, such as joint pain,
functional impairment and structural damage which is hallmarked by bone erosions in RA andax: þ31 71 5266752.
uwers), J.H.von_Hegedus@lumc.nl (J. von Hegedus), R.E.M.toes@lumc.nl (R.
.Ioan@lumc.nl (A. Ioan-Facsinay).
.
H. Brouwers et al. / Best Practice & Research Clinical Rheumatology 29 (2015) 741e755742osteophytes in OA. Moreover, both diseases display joint space narrowing, reflecting cartilage loss.
Another common feature of these diseases is the presence of inflammation in the majority of the
patients. While the role of inflammation in the pathogenesis of RA has been established previously, its
presence and possible role in OA has been only recently revealed. Several studies during the past 10
years have shown an association between synovial inflammation and pain on one hand and radio-
graphic progression on the other hand, thus establishing the pivotal role of inflammation in OA
(reviewed in Refs. [1,2]).
Fatty acids acquired through diet are usually transported through the body in triglycerides or
phospholipids incorporated in lipoproteins, but can also be found in free form in blood. Moreover, they
are present both in bound and free form in cells, where they perform various functions as energy
source, membrane constituents or signalling molecules. They are the essential building blocks for
higher-order lipids such as phospholipids, sphingolipids, glycerolipids and glycolipids. Moreover, they
could be metabolized into bioactive lipid mediators such as oxylipins, including eicosanoids (prosta-
glandins, thromboxanes and leukotrienes) and other lipids with more anti-inflammatory and pro-
resolving activity such as lipoxins, resolvins, maresins and protectins. Enzymes such as phospholi-
pases (PLAs) which release fatty acids from phospholipids, cyclooxygenases (COXs) and lipoxygenases
(LOXs) that oxidize fatty acids are involved in the generation of oxylipins. Fatty acids, higher-order
lipids and oxylipins can interact with inflammatory as well as tissue-resident cells, thereby contrib-
uting to various processes in the body, including inflammation, wound healing, pain, etc, and poten-
tially playing a role in RA and OA. In general, it is believed that saturated fatty acids, n-6
polyunsaturated fatty acids (PUFAs), such as arachidonic acid (AA), and AA derivatives (prostaglandins
and leukotrienes) have a pro-inflammatory effect. By contrast, unsaturated fatty acids, n-3 PUFA, such
as docosahexaenoic acid (DHA) and eicosapentaenoic acid (EPA), and the oxylipins derived from them
(resolvins, maresins and protectins) are believed to have an anti-inflammatory function. The latter are
also believed to be pro-resolving, thereby actively helping wound healing and return to tissue ho-
meostasis after an inflammatory response.
In this review, we will present data supporting the role of lipids in RA and OA. To this end, we will
summarize findings from three lines of evidence. First, data related to the presence of various fatty
acids and their derivatives (lipid mediators) in blood or synovial fluid (SF) of RA and OA patients will be
summarized. Next, the association of these lipids with clinical disease parameters will be presented, as
well as in vivo intervention studies both in humans and mouse models of disease. Finally, in vitro
studies indicating the effects of these lipids on human joint tissues will be presented (summarized in
Fig. 1). The role of cholesterol and lipoprotein metabolism in RA and OA has been reviewed elsewhere
[3,4] and will not be discussed in this review.
Lipids and lipid classes described in serum of healthy individuals
In an extensive study in which the major six lipid categories as defined by the Lipid Maps were
measured in plasma of healthy individuals, more than 500 lipid species were identified [5]. The
measured sample was obtained from the National Institute of Standards and Technology (USA); the
pooled plasma sample was obtained and stored after overnight fasting in a standardized fashion, from
100 healthy individuals (age: between 40 and 50 years) including an equal number of men and women
whose ethnicity was representative of the US population. The most abundant (on a molar basis) was
sterols (including cholesterol), followed by triglycerides (part of lipoproteins), glycerophospholipids,
free fatty acyls and sphingolipids, and the least abundant was diacylglycerols and prenols. In terms of
free fatty acids, oleic acid, followed by palmitic acid and stearic acid were the most abundant and
comprised approximately 78% of all free fatty acids after overnight fasting. The most abundant PUFA
were linoleic acid (LA) and AA, but EPA and DHA, which are derived from fish oil and are known for
their anti-inflammatory effects, were also detectable. Lipid mediators such as oxylipins were also
detected in plasma, with 15-deoxy-PGD2 (prostaglandin D2) being the major metabolite generated by
COX, while 5-HETE was the most prominent eicosanoid of the LOX pathway found in plasma [5].
This review focuses on selected lipids in the six lipid classes: fatty acids either in free form or
incorporated in higher-order lipids (especially phospholipids), as well as their bioactive lipidmediators
in RA and OA (Table 1).
Fig. 1. Summary showing lipids and relevant enzymes (in italic) in the context of rheumatoid arthritis (A) or osteoarthritis (B)
discussed in this review. Lipids are incorporated in phospholipids in the membrane. The enzyme autotaxin can convert lysos-
phosphatidylcholine (LPC) to lysophospatidic acid (LPA), and phopholipases (PLA) can both generate LPC from phosphatidylcholine
(PC) and release fatty acids from the membrane phospholipids. These fatty acids can be metabolized into oxylipins by different
cyclooxygenases (COX) and lipoxygenases (LOX). Symbols represent different tissues that have been shown to be affected by lipids.
The effects of lipids on tissues are indicated by colours: red ¼ inflammatory, green ¼ anti-inflammatory/resolving, blue ¼ both
inflammatory and anti-inflammatory/resolving.
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Lipids in serum of RA patients
Direct comparisons between different lipids in RA serum/plasma and healthy controls were only
made in few studies and generally included relatively low numbers of patients (between 10 and 16). In
a metabolomics study, it was found that the levels of lipids in general were lower in serum of newly
presenting RA patients compared to healthy controls although a systematic investigation of different
lipid classes was not performed. To exclude the effect of disease-modifying anti-rheumatic drugs
(DMARDs) on metabolic status, patients who were administered DMARDs were excluded from this
analysis [6]. In another study in 166 RA patients, the levels of free fatty acids were found to be similar in
RA patients and healthy controls [7], indicating that free fatty acids are not quantitatively different in
the diseased state. Fatty acids in phospholipids and sphingomyelins were also described in serum of
healthy individuals and RA patients [8]. Of the different phospholipids studied, only the ratio phos-
phatidylcholine (PC)/lysophosphatidylcholine (LPC, generated from PC by the PLA enzyme) was found
to be lower in serum of RA patients compared to healthy individuals [9], indicating a higher activation
of PLA in RA patients. This could result in higher levels of free fatty acids that can further be metab-
olized into bioactive lipids. Indeed, lipid mediators such as prostaglandins, PGD2 and PGE2 [10],
generated by COX enzymes, were shown to be present in serum of RA patients, indicating that not only
precursor fatty acids might be higher in RA compared to healthy individuals, but also certain enzymes
involved in generation of bioactive lipids. However, bioactive lipids were mainly studied in SF.Lipids in SF of RA patients
Broad lipidomic studies in SF of RA patients were performed in which most of the lipid species
described in serum/plasma could be detected [8,10e13]; several phospholipid and fatty acid species
Table 1
Summary of lipids included in the present review and their corresponding lipid classes. DHA: docosahexaenoic acid; EPA:
eicosapentaenoic acid; PC: phosphatidylcholine; LPC: lysophosphatidylcholine; LPA: lysophospatidic acid.
Lipid class
(according to Lipid Maps)
Lipids included
in this review
Fatty acyls Fatty acids, oxylipins: eicosanoids
(prostaglandins, leukotrienes, lipoxins),
derivatives of DHA, EPA (resolvins, maresins, protectins)
Glycerolipids e
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sphingomyelins [12] and their levels were higher in RA SF than controls [12,13]. The ratio of PC/LPC was
higher in RA SF than in controls, in contrast to what was found in serum [12,13]. A detailed analyses of
the species of lipids revealed that RA SF was relatively enriched in LPC-containing saturated fatty acids,
while saturated PC was lower than in controls, indicating that saturated fatty acids were possibly more
efficiently released from PC in RA. The length of fatty acids contained in PC species was not different
between RA SF and controls, but RA SF contained relatively more short-chain fatty acids in LPC
compared to controls [12,13]. As a longer chain length and higher saturation grade are believed to be
beneficial for the lubricating properties of phospholipids, these data could indicate that the phos-
pholipids present in RA SF are less potent lubricators and provide less protection against mechanical
damage than in healthy controls. All studies were small and included approximately 20 patients.
Eicosanoids such as prostaglandins and leukotrienes were intensively investigated in SF of RA pa-
tients and were recently reviewed [14]. Prostaglandin E2 (PGE2) [14,15] as well as PLA2 and COX, en-
zymes involved in its generation, were found to be higher in SF or were higher expressed in synovium
of RA patients (mPGES) [16e20]. Likewise, the enzyme converting PGE2 into the inactive 15-PGDHwas
higher in RA synovium, indicating that regulatory mechanisms targeting PGE2 are also activated in this
disease. Interestingly and in line with this observation, the more anti-inflammatory prostaglandins,
PGD2 and its metabolite 15-deoxy-PGJ2 were also found in the RA joint. Expression of PGD2 was
detected in cells in RA joints; however, no evidence was found for enhanced biosynthesis of 15-deoxy-
PGJ2. Next to prostaglandins, leukotrienes such as LTB4, LTD4 and LTE4 were found in SF of RA patients
[14].
Interestingly, anti-inflammatory products of LOXs were also described in SF of RA patients. These
included the anti-inflammatory and pro-resolving mediators lipoxin A4 (LXA4) and the mediators
derived from the n-3 PUFA DHA: maresin 1 (Mar1) and resolving D5 (RVD5) [11]. Although this study
was performed in only five patients and the effects of pro-resolving lipids on RA development or
progressionwere not yet investigated, their potent immunemodulatory functions [21] identify them as
promising therapeutic agents for chronic inflammatory diseases.
Besides the PLA, COX and LOX enzymes, autotaxin makes an important contribution to bioactive
lipids in RA. It can convert membrane phospholipids such as LPC to lysophospatidic acid (LPA), as well
as sphingosylphosphorylcholine to yield sphingosine-1-phosphate (S1P). S1P can act as an intracellular
second messenger or extracellular lipid mediator via G-coupled receptors and is involved in regulation
of pro-inflammatory pathways and cell migration. Its possible role in RA is discussed later. Both LPA
and S1P, as well as autotaxin were shown to be present in SF of RA patients [22e24], while higher
autotaxin levels were shown in RA SF (n ¼ 16) and serum (n ¼ 26) compared to controls [25].
Lipids in serum/SF of OA
Several lipidomic studies in OA patients have been performed over the recent years. Although most
of them study SF, one study investigated the phospholipid profile of hip and knee OA patients (n ¼ 59
women) in plasma [26]. Similarly to RA, the LPC/PC ratio was higher in both mild and moderate OA
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with 30 and 48 OA patients, the levels of phospholipids were found to be elevated in SF of OA patients
compared to post-mortem controls [12,13], similar to what was found for RA.
Few studies have investigated oxylipin levels in OA. In one study with 10 OA patients, 8-iso-PGF2a
and 15-keto-dihydroPGF2a were detected in both serum and SF, but the levels did not correlate in these
two fluids [27]. This indicates that there might be local production of these lipids, rather than systemic
diffusion. Noteworthy is that levels of both metabolites were higher in serum of OA patients compared
to controls. Higher levels of these metabolites in serum of OA patients could indicate higher systemic
oxidative damage and inflammatory responses. For some patients, the levels of both compounds, but
especially 15-keto-dihydroPGF2a tended to be somewhat higher in SF compared to serum. It is difficult
to interpret these data due to the lack of healthy SF and low numbers of patients. More recently, a study
investigated the 15-LOX product 15-HETE and the COX product PGE2 in plasma of symptomatic OA
patients and controls [28]. Bothmetabolites were elevated in patients (three different cohorts with 291
patients in total) compared to controls, which could be a systemic reflection of local inflammation in
the knee. Similarly, leukotriene B4(LTB4) has also been described in SF of some OA patients, although no
comparison with healthy controls was performed [29]. Together, these data indicate that pro-
inflammatory lipids are present in OA patients, although a more extensive investigation of the pres-
ence of other lipid classes, such as prostaglandins and anti-inflammatory oxylipins, in OA patients is
warranted.
Fatty acids and phospholipids
Dietary fatty acids, such as the n-3 PUFA EPA and DHA derived from fish oil. These n-3 PUFAs are
believed to have anti-inflammatory properties, while the n-6 PUFA AA is believed to be more pro-
inflammatory. Long-chain fatty acids such as AA, EPA and DHA are incorporated in phospholipids
and these are essential constituents of membranes. In healthy individuals on a typical Western diet,
about 10e20% of phospholipids in membranes of leukocytes are composed of AA, while 0.5e1% is EPA
and 1.5e3% is DHA [30]. Dietary intake of EPA and DHA leads to an increase of these fatty acids in
cellular membranes and this occurs usually at the expense of AA. This incorporation begins within days
and is dose dependent [31,32]. Because erythrocytes have a lifespan of 100e120 days, their membrane
phospholipid composition is generally used to monitor the dietary intake of lipids [32,33].
Association with clinical characteristics and intervention studies in RA
Most studies investigating the types of fatty acids present in RA patients and association with
clinical parameters focussed on dietary fatty acids.
Several clinical trials have been performed with either fish oil or n-3 supplementation in RA pa-
tients. These randomized control trials have been recently summarized in a systematic review byMiles
and Calder [31]. The authors analysed 23 studies, in which EPA and DHA doses varied largely, between
<1 and >7 g/day and were administered mostly orally as fish oil supplements. The duration of the
studies varied between 4 and 52 weeks and the placebo controls were usually other types of oils, such
as corn, olive oil and paraffin oil. The sample size of these studies was typically around 20e30 patients/
group, excepting few studies with participation of less or more patients. Many studies had method-
ological shortcomings and no meta-analysis was performed. In general, the observed beneficial effects
of n-3 PUFAwere related to morning stiffness, the number of tender/swollen joints, grip strength, pain
or disease activity. The effects were overall modest.
Since this systematic review, another study investigated the effect of intake of moderate amounts of
n-3 PUFA (2.090 g EPA and 1.165 g DHA) in combinationwith regular anti-inflammatory therapy in 109
RA patients. High-oleic acid sunflower oil was used as control. Although there was an increase in n-3
PUFA and a relative decrease in n-6 PUFA AA in erythrocyte membranes in the treatment group, there
was no significant effect on clinical symptoms, non-steroidal anti-inflammatory drug (NSAID) usage,
cytokines, eicosanoids and bone turnover markers in this group [34], which might be attributable to
the low dose of n-3 PUFA administered. Similar results regarding the incorporation of n-3 PUFA in
erythrocyte membranes at the expense of AAwere found in another study with a relative low number
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groups: one treatedwith 3 g n-3 PUFA/day, onewith 3.2 g g-linolenic acid (n-6 PUFA)/day and onewith
a combination of a low dose n-3 PUFA (1.6 g) and g-linolenic acid (1.8 g)/day. The treatment duration
was 12 weeks. A relative decrease of AA/EPA ratio was observed in the n-3 PUFA-treated group, similar
to earlier studies. In addition, an enrichment in g-linolenic acid in plasma lipids, cholesterol mem-
branes and erythrocyte membranes was observed, and this enrichment was dependent on the dose
indicating that this n-6 PUFA is also dose-dependently incorporated in cellularmembranes upon intake
[35].
Interestingly, several recent studies have investigated the effects of n-3 PUFA on early RA patients or
on development of RA and related features in pre-RA individuals. Early RA patients (n ¼ 140) treated
with DMARD therapy were additionally treated with 5.5 g/day EPA þ DHA or with 0.4 g/day EPA and
DHA (control group). The primary outcome was failure on triple DMARD after 3 months. Failure was
lower and the rate of remission was higher in the n-3 PUFA-treated group compared to the control
group after 3 months of treatment [36]. Remarkably, EPA in plasma phospholipids was inversely
associated with time to remission and to DMARD failure, while similar results, albeit not significant,
were also obtained for DHA, indicating that EPA might be more effective than DHA as disease
modulator.
Several studies investigated the effect of intake of fish containing n-3 PUFA on the risk of devel-
opment of RA in healthy individuals. In a meta-analysis involving both prospective and caseecontrol
studies, the authors found that for each serving of fish per week, the relative risk of RA became 0.96
(95% confidence interval (CI) 0.91; 1.01), while there was a 20e24% lower risk (0.76 (95% CI 0.57; 1.02))
of RA for 1e3 servings of fish/week compared to no servings [37]. In an observational population-based
cohort study (32,232 women aged 54e89 years), self-reported intake of >0.21 g/day of n-3 PUFA led to
a 35% (95% CI 10e52%) lower risk of developing RA than lower intake. Moreover, long-term consistent
intake of >0.21 g/day of n-3 PUFA led to a 52% (95% CI 29e67%) lower risk of RA than lower intake,
while long-term consistent intake of >1 serving of fish/week led to 29% lower risk (risk ratio (RR) 0.71;
95% CI 0.48e1.04) compared to <1 serving/week [38]. Although the intake was based on self-reported
data and nomeasurements of n-3 PUFA in phospholipids were presented, these studies suggest that n-
3 PUFA could be beneficial for lowering the risk of RA development in pre-disease individuals and this
effect is probably dose dependent. This would also be in line with a more recent study in which in-
dividuals at risk for developing RA (non-diseased first-degree relatives of RA patients and HLA-DR4þ
individuals) and positive for anti-CCP antibodies (n ¼ 30) were compared to seronegative individuals
(n ¼ 47) for the amount of n-3 PUFA intake (self-reported) and the percentage of n-3 PUFA in eryth-
rocyte membranes. The findings indicate that anti-CCPþ individuals were less likely to report n-3 PUFA
intake, and the anti-CCP positivity was inversely correlated to the percentage of n-3 PUFA in eryth-
rocyte membranes [39]. Altogether, these findings suggest that n-3 PUFA might affect the risk for
development of RA, as well as the clinical parameters of the disease in RA patients.
Supporting these data, interventions with DHA and EPA have been also shown to reduce the onset,
incidence and severity of collagen-induced arthritis (CIA) in mice [40,41].
Other fatty acids have only scarcely been studied. Although not yet investigated in relation to
human RA, a-lipoic acid (ALA) showed promising results in mice, as it inhibited joint inflammation and
bone destruction in the CIA model both when administered intra-peritoneally [42] and through diet
[43]. Although the mechanisms are unclear, ALA inhibited synovial inflammation in both studies, as
well as human osteoclast differentiation in vitro [42] and in mice in vivo [43].
Supporting a possible role for LPA/autotaxin axis in arthritis, inhibition of the LPA receptor inhibits
development of disease in the K/BxN serum transfermodel through effects on cartilage destruction and
bone erosions, possibly through inhibition of osteoclast differentiation and activity and promotion of
osteoblast differentiation [44]. Similarly, mice lacking autotaxin in the mesenchymal cell compartment
had less arthritis on a hTNF-a (tumour necrosis factor-a) transgenic background, as well as in the CIA
model of arthritis and this effect was likely mediated by LPA effects on synovial fibroblasts [25].
Interestingly, preventive oral administration of LPC precursor PC to CIA mice also inhibited severity of
CIA, possibly through inhibition of leukocyteeendothelium interactions and nitric oxide (NO) pro-
duction [45]. These data indicate that the PC/LPC/LPA metabolic pathway might represent a promising
target for intervention in RA patients.
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Two studies have measured phospholipids in both early OA and late OA patients, with early and late
being defined by the Outerbridge classification scale. One of these studies assessed the difference in lipids
between early (n ¼ 17) and late OA (n ¼ 13) and showed that concentrations of 66 phospholipid species
were different between these stages and that the total lipid content was higher in late OA compared to
early OA [12]. In addition, the PC/LPC ratio was higher in late OA then early OA, possibly indicating a
higher activation of PLA2 in early compared to late disease. A metabolomic approach can also be used to
classify OA patients based on theirmetabolite profile. Using this approach, it was found that a group of 80
OA patients was divided into two distinct groups particularly based on the levels of carnitines and its acyl
esters acylcarnitines (involved in fatty acid metabolism) in knee SF [46]. The group with lower acylcar-
nitine levels could be further divided into two subgroups based on their glycophospholipid and sphin-
gomyelin (SM) levels. Although the groups were not correlated to any clinical OA characteristics, these
data indicate that OA patients can be divided in metabolically distinct groups. An earlier study by
Kosinska et al. did correlate the levels of SMwith relevant OA features [47]. All SM species measured in SF
were 2.4-fold higher in early OA patients (n¼ 17) compared to controls and twofold higher in late (n¼ 13)
versus early OA patients. Early and late OA patients were classified with the Outerbridge score.
Most reports studying lipids and their association with clinical parameters have studied fatty acids,
rather than phospholipids or other higher-order lipids. To the best of our knowledge, only one study
investigated the association of plasma fatty acid levels with clinical features in OA patients. This study
measured fasting plasma levels of fatty acids in 472 individuals, including OA patients, as well as in-
dividuals at risk of developing knee OA [48]. N-3 fatty acids, in particular DHA, were inversely corre-
lated with patellofemoral cartilage loss, but not tibiofemoral cartilage loss or synovitis at 30-month
follow-up, suggesting a protective effect of this n-3 fatty acid on selected structural findings. The
levels of the n-6 fatty acid AA, which is believed to be more pro-inflammatory, were positively
correlated with synovitis. In line with this result, in another study on knee OA patients, the AA levels
were found to correlate with histologic disease severity [49].
While fish oil or n-3 PUFA supplementation has been intensively studied in RA patients, only a few
intervention studies have been performed in OA patient groups. Most of these studies aimed at reducing
pain. Forty-seven patients with knee or hip OA, consuming 1200 mg fish oil (total n-3 18% EPA and 12%
DHA) a day for 12 weeks in a randomized trial, showed no improvement on either visual analogue scale
(VAS) for patient self-assessment of pain or the health assessment questionnaire (HAQ) for patient self-
assessment of activity [50]. In addition, a double-blind placebo-controlled trial in 86 OA patients failed
to detect any benefit from taking either 10 ml cod liver oil (786 mg EPA) or olive oil per day for 24 weeks,
next to the regular intake of NSAIDs [51]. By contrast, one study reported the beneficial effects of fish oil in
OA patients. A randomized, double-blind multicentre trial investigated the effect of a low dose of 0.45 g of
fish oil (18% EPA and 12% DHA) per day versus a high dose of 4.5 g on pain and function scores in 202 knee
OA patients after 2 years [52]. Both groups benefitted from the treatment, although unexpectedly, the
group receiving low-dosefish oil benefitted themost, with significantly lower pain scores (WOMAC index)
at 18 and 24 months and better function limitation scores after 24 months. No beneficial effects were
observed on cartilage volume or bonemarrow lesions. It should bementioned, however, that the low-dose
fish oil preparation also contained Sunola oil which includes n-9 monounsaturated oleic acid. Therefore, it
is difficult to conclude whether the observed effects were due to the n-3 fatty acids alone [53].
Despite the unclear effects of n-3 PUFA on pain in humans, they were shown to reduce radiographic
damage in mouse models of OA, both in spontaneous [54] and surgically induced models [55]. Inter-
estingly, their beneficial effect was correlated to a better wound healing, while saturated fatty acids and
n-6 fatty acids had opposite effects on OA severity and wound healing [55], suggesting the existence of
common mechanisms involved in both processes. Moreover, it suggests a possible benefit of n-3 PUFA
on structural damage, which still needs to be investigated in humans.
Effects on RA human tissues in vitro
Free fatty acids have been described in serum and SF of RA patients and they could affect joint
tissues and immune cells involved in disease pathogenesis. Indeed, in vitro treatment of RA synovial
H. Brouwers et al. / Best Practice & Research Clinical Rheumatology 29 (2015) 741e755748fibroblast with free fatty acids induced pro-inflammatory cytokines interleukin (IL)-6, IL-8, monocyte
chemoattractant protein (MCP)-1 and matrix metalloproteinases (MMPs) and this effect was inde-
pendent of the length or saturation degree of the fatty acid, but variable between donors [56]. For
chondrocytes, lipids isolated from SF could inhibit chondrocyte proliferation [57], while saturated fatty
acids induced IL-6 [56]. Endothelial cells only responded to high concentrations of fatty acids such as
palmitic acid and linoleic acid, but not oleic acid [56]. Taken together, these data indicate that different
cell types respond differently to individual fatty acids and that combinations of fatty acids could have a
different effect than the individual components. Moreover, free fatty acids and especially dietary fatty
acids can potently influence bone metabolism through regulation of PGE2 and leukotrienes, stimu-
lating bone resorption or prostaglandin-mediated regulation of insulin-like growth factor 1 (IGF-1), a
growth factor that stimulated bone formation [58]. The role of these processes in bone metabolism in
RA remain to be investigated.
Besides their effect on joint tissues, fatty acids also have immune modulatory effects. Effects of n-3
PUFA on cells derived from RA patients have been investigated, while much less attention has been
given to other fatty acids. N-3 PUFA had an anti-inflammatory effect on cytokine secretion by mono-
cytes derived from RA patients [59], while inhibiting formation of reactive oxygen species [60] and the
AA-mediated induction of TNFRI and eII on RA neutrophils [61]. Fatty acids can also affect T cell
function [62] and B cell function [63], although the effects of fatty acid type, saturation and length, as
well as the specific effects on T and B cells from RA patients remain to be addressed.
Some of the phospholipids found in serum or SF have been shown to affect joint tissues and cells
thereby potentially contributing to RA. Among these, LPC and LPA have received special attention, as
they were described to have potent immune modulatory effects (reviewed in Ref. [64]). For example,
LPA has been shown to induce COX2 expression in RA synovial fibroblasts, either alone or in combi-
nation with pro-inflammatory cytokines such as IL-1a or b [22], to induce their proliferation and
enhance production of IL-6, VEGF, CCL 2 and MMP3, as well as expression of VCAM and migration [65].
Although the effects of LPC on human RA tissues were not yet investigated, LPC was shown to induce
COX2 expression in vascular endothelial cells [66] and macrophages [67], which would suggest a
possible pro-inflammatory role of this lipid in RA.
Another product of autotaxin found in RA SF, S1P, was also shown to have effects on RA-derived
tissues, including stimulation of proliferation of RA synovial fibroblasts [68] and enhancing COX2
and PGE2 production in synovial fibroblasts [68] and chondrocytes [69], or by decreasing aggrecan
production by chondrocytes [69] and stimulating osteoblast differentiation [70].
Together, these data indicate a pro-inflammatory effect of the PC/LPC/LPA axis in RA.
Effects on OA human tissues in vitro
While intervention studies with fatty acid supplementation mainly focussed on reducing pain in
patients, the in vitro studies performed focussed predominantly on the effects of fatty acids on OA
tissues and the mechanisms underlying these effects. Chondrocytes were most studied in this respect
and they were usually stimulated with cytokines believed to have a prominent role in OA. Chon-
drocytes from knee cartilage explants of OA patients were shown to take up linoleic, oleic and palmitic
acid, regardless of whether they were stimulated with TNF-a [71]. Upon oleic acid exposure, TNF-a-
stimulated chondrocytes secrete less GAG and downregulate the expression of MMP-1 and COX-2,
indicating an anti-inflammatory effect. Palmitic acid had similar effects on GAG release and MMP-1
expression but did not affect PGE2 release or COX-2 expression. By contrast, AA precursor linoleic
acid increased the release of PGE2 by TNF-a-stimulated chondrocytes. These results suggest that local
fatty acid concentrations can contribute to cartilage damage. In another study, the effect of palmitate
and oleic acid on chondrocytes of OA patients was investigated in comparison to post-mortem control
chondrocytes [72]. The data indicated that IL-1b together with palmitate synergistically increased IL-6
and COX-2 expression, whereas oleic acid did not in both donor types, indicating a rather pro-
inflammatory effect of palmitic acid. In addition, increased apoptotic cell death was observed in
chondrocytes stimulated with both IL-1b and palmitate in the post-mortem cartilage. The contrasting
effects of palmitic acid on chondrocytes in these two studies could be due to differences in stimulus
used to mimic OA-related inflammation in chondrocytes.
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Association with clinical characteristics and intervention studies in RA
It is generally accepted that PGE2 contributes to the disease process in RA [14]. This is primarily
based on studies in mouse models of arthritis, as well as on intervention studies in humans. De-
ficiencies in enzymes involved in PGE2 generation, such as cPLA2 [73], COX-1 [74] and COX-2 [75] or
mPGES-1 [76], as well as blockers of PGE2 receptors [77] were associated with diminished disease in
mousemodels of arthritis. Moreover, intervention studies conducted using pharmacological inhibitors,
which have also been used in humans, indicated that PGE2 contributes to pain in antibody-induced
models of arthritis, especially in the inflammatory phase of the disease [78,79]. Taken together,
these data indicate that PGE2 plays a role in this disease. Intriguingly, however, it was also suggested
that PGE2 has a dual role in arthritis, being pro-inflammatory in the induction phase, while also
contributing to disease resolution, by inducing the pro-resolving lipid mediator LXA4 during the later
phases [80]. LXA4 has also been shown to have anti-inflammatory and pro-resolving properties in other
murine arthritis models, such as zymosan-induced arthritis [81].
In humans, most evidence for a deleterious contribution of PGE2 to pain was obtained from studies
investigating the effect of NSAIDS in RA (reviewed in Ref. [82]). The involvement of PGE2 in inflam-
mation in RA is less clear, although some studies indicate that local administration of corticosteroids in
knee RA also diminishes swelling besides pain and this is parallelled by a reduction in mPGES-1, COX-1
and COX-2 expression, as well as less PGE2 production [83]. In line with this, randomized control trials
indicate that drugs aimed at blocking COX activity also affect the number of swollen joints [84].
Because COX is involved in the generation of several lipid species, including anti-inflammatory ones,
such as PGJ2 or the pro-resolving E series resolvins, it would be highly interesting to test the clinical
efficacy of inhibitors of mPGES or antagonists of PGE2 receptors, which would be expected to modulate
more specifically PGE2-mediated effects.
Besides prostaglandins, leukotrienes, especially LTB4, could also play a role in RA. Serum levels of
LTB4 were associated with higher disease activity [85], while SF levels of LTB4 were correlated with
inflammatory markers (e.g. cellular infiltrate) in RA patients [86]. However, these data should be
interpreted carefully, as 5S,12S-diHETE, a less active isomer of LTB4, was also described in SF of RA
patients [11]. It is difficult to distinguish these two lipids with enzyme-linked immunosorbent assay
ELISA or high-performance liquid chromatography (HPLC) techniques (own unpublished data). Murine
studies provide evidence for the role of LTB4 in RA, wherein 5-LOX or LTA4 hydrolase deficiency pre-
vented the development of antibody-induced arthritis and this could be restored by transfer of neu-
trophils capable of secreting LTB4, thus indicating a role for this lipid and neutrophils in this model [87].
Similarly, the absence of the LTB4 receptor BLT1, especially on neutrophils, also resulted in less arthritis
in the K/BxN and CIA models [88,89]. Data in RA patients are less clear. Zileuton, a 5-LOX inhibitor, did
not decrease joint tenderness and pain after a 4-week treatment in patients with active RA. However,
there was a nonsignificant decline in the number of joints effected [90].
Association with clinical characteristics and intervention studies in OA
Studies investigating the role of oxylipins in OA patients are scarce. In a recent study, plasma levels
of PGE2 and 15-HETE, as well as TNF-a, IL-1b and COX-2 expression in peripheral blood leukocytes
(PBL) were investigated in three separate cohorts of knee OA patients [28]. Higher levels of plasma
PGE2 and 15-HETE were associated with the presence of knee OA, while a higher expression of TNFa,
IL-1b and COX-2 in PBL at baseline predicted more rapid progression of joint space narrowing 24
months later.
In a recent systematic review, the efficacy of pharmacological interventions for knee OA was
investigated [91]. In total, 137 randomized controlled trials were summarized. Treatments included
COX inhibitors such as diclofenac, ibuprofen, naproxen and celecoxib. All treatments were more
efficient than placebo in controlling pain, while intra-articular treatments were superior to oral
treatments. Regarding function and stiffness, all treatments with COX inhibitors were more
effective than oral placebo, thus indicating a possible beneficial effect of these pharmacological
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a natural 5-LOX inhibitor was evaluated in 75 OA patients [92]. The inhibitor showed pain
reduction in the treated group compared to placebo; however, effects on structural damage in
patients remain to be defined.
A third approach is to inhibit both COX and 5-LOX enzymes, as several studies now showed that
the dual COX/5-LOX inhibitor licofelone is equally effective in diminishing pain as the COX inhibitor
naproxen, but has less gastrointestinal-related adverse effects [93]. Moreover, in one study with 355
OA patients, licofelone was more efficient than naproxen in reducing cartilage volume loss in the
global joint and lateral compartment at 6, 12 and 24 months [94]. However, the effects of this
compound on OA structural damage compared to placebo were not yet investigated in humans.
Nevertheless, two studies on OA models in dogs indicated less cartilage lesions and decreased levels
of PGE2, LTB4, collagenase 1 and IL-1b in the joint in the treated group [95], as well as reduced size of
cartilage lesions and development of osteophytes [96]. These findings are supported by in vitro
studies, in which IL-1b-treated chondrocytes displayed decreased MMP-13 production upon treat-
ment with licofelone [97].Effects on RA human tissues in vitro
Several studies investigated the effect of prostaglandins, especially PGE2, on tissues derived fromRA
patients. In line with what was observed in vivo, PGE2 can display both pro- and anti-inflammatory
effects. PGE2 has been shown to upregulate IL-6 and mPGES in RA synovial fibroblasts [98,99] and
IL-6 in chondrocytes [100], while inhibiting RA fibroblast growth [101] andMMP-1 expression (JI 2009;
15:1328) as well as osteoclast development [101]. Besides immune cells, PGE2 can have pro-
inflammatory effects also on dendritic cells, by inducing IL-23 production [102] and anti-
inflammatory effects on monocytes and macrophages [103] by reducing the p40 subunit of IL-12
and IL-23. These data suggest that the inhibition of PGE2 in RA should be carefully considered. For
15-deoxy-PGJ2, predominantly anti-inflammatory effects were shown, such as downregulation of IL-6
[100] and induction of apoptosis in chondrocytes [104], as well as inhibition of TNFa-induced MMP-13
production in RA synovial fibroblasts [105].
In vitro studies indicate that leukotriene B4 has a pro-inflammatory effect on RA tissues. LTB4
induced TNFa and IL-1b in RA synovial fibroblasts [106] and was capable of inducing osteoclast dif-
ferentiation [107].
The effect of anti-inflammatory lipid mediators was much less studied. Intriguingly, one study
indicated that 15-HETE, a derivative of 15-LOX, could upregulate MMP-2 in RA synovial fibroblasts
[108], suggesting a possible pro-inflammatory role of this lipid in RA.Effects on human tissues in vitro OA
Several studies investigated the effect of oxylipins on OA tissues in vitro. 15-LOX products as well as
PGD(COX product) dose dependently decreased IL-1b-induced MMP-1 and MMP-13 production by
chondrocytes isolated from OA cartilage [109], thus suggesting a beneficial role for these lipids in OA.
By contrast, the 5-LOX product LTB4 was shown to increase IL-1b secretion by OA synovial membranes
[110], while increasing osteocalcin secretion by OA osteoblasts [111], thus indicating that LTB4 might
contribute to inflammation and structural damage in OA patients.
PGE2 is the most studied oxylipin in the context of OA and has been shown to induce IL-6, VEGF and
M-SCF production by human OA synovial fibroblasts [112] and to have deleterious effects on OA
chondrocytes. On articular cartilage of OA patients, PGE2 inhibits proteoglycan release and stimulated
MMP-13 production and collagen type II breakdown via engagement of EP receptors. Blocking the EP4
receptor could inverse these effects, thus indicating it as a potential therapeutic target, more specific
than COX inhibitors [113]. However, it was also shown that PGE2 at concentrations lower than found in
SF are important in maintaining normal chondrocyte phenotype [114]. Taken together, these data
indicate that future studies on PGE2 and its signalling pathways are required to fully understand its
contribution to OA.
Practice points
 Lipid mediators such as prostaglandins and leukotrienes are increased in synovial fluid of
both RA and OA patients.
 Anti-inflammatory lipid mediators were detected in RA synovial fluid, thus indicating acti-
vation of regulatory mechanisms.
 PGE2 can have both deleterious and beneficial effects.
 COX is involved in pain perception in RA and OA.
 Targeting COX and LOX enzymes can affect both pro- and anti-inflammatory/pro-resolving
lipid synthesis.
 N-3 PUFA supplementation is suggested to have (small) beneficial effects in RA patients.
Research agenda
 The effects of n-3 PUFA supplementation in RA and OA should be further investigated in
high-quality randomized controlled trials.
 Therapeutical interventions aimed at inhibiting lipid mediator receptors rather than the en-
zymes involved in their generation should be studied in humans.
 The effects of PGE2 in inflammation in RA need further investigation.
 The involvement of COX and LOX enzymes and their lipid products in development or
severity of OA needs further pre-clinical investigation.
 The overall effect of anti-inflammatory/pro-resolving lipids on OA and RA tissue needs to be
addressed.
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Fatty acids, phospholipids and oxylipins can be detected in RA and OA patients. Most evidence
suggests the activation of the COX/PGE2 and autotaxin/LPA axes in RA and the COX/PGE2 and LOX
pathways in OA. Inhibition of the COX pathway is beneficial for pain in both diseases, while the effects
of inhibition of the LOX pathway are unclear.Whether and how lipids generated by these two pathways
are involved in structural damage and inflammation in these diseases is still under investigation.
Moreover, the role of anti-inflammatory (oxy)lipids in RA and OA must be studied.Acknowledgements
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